Resmed

Resmed FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Resmed (RMD) as of Oct 9, 2026 is 108.29 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 118.63 % — a change of -8.72% (lower).

FCF Conversion

108.29 %

YoY

-8.72%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Resmed is 2026 108.29 % . FCF Conversion Rate (FCF/EBITDA) of Resmed was 2025 118.63 % . It decreases by -8.72% lower compared to the previous year.

The Resmed FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
94.34 USD
Jan 1, 2020
112.01 USD
Jan 1, 2021
130.64 USD
Jan 1, 2022
25.03 USD
Jan 1, 2023
62.31 USD
Jan 1, 2024
126.00 USD
Jan 1, 2025
118.63 USD
Jan 1, 2026
108.29 USD
The Resmed FCF Conversion history
YEARFCF ConversionYoY
108.29 %-8.72%
118.63 %-5.85%
126.00 %+102.20%
62.31 %+148.93%
25.03 %-80.84%
130.64 %+16.64%
112.01 %+18.72%
94.34 %-31.33%
137.38 %+37.27%
100.09 %-26.53%
136.23 %+54.47%
88.20 %-1.80%
89.82 %—
Access this data via the Eulerpool API

Resmed Stock analysis

What does Resmed do? ResMed Inc. is a global leading provider of medical devices for the treatment of sleep disorders and respiratory diseases. The company was founded in Australia by Peter Farrell, a former employee of the University of New South Wales, in 1989. Today, ResMed is headquartered in San Diego, California, and employs over 7,500 people worldwide. Business model: ResMed's business model is based on providing medical products and solutions for the treatment of sleep apnea and other respiratory diseases. The company develops and distributes masks, devices, and accessories that help patients breathe better and achieve restful sleep. ResMed also offers cloud-based software solutions and services to assist doctors and sleep labs in diagnosing and monitoring patients. Products and divisions: ResMed's product range can be divided into four main divisions: Sleep & Respiratory Care, Software as a Service (SaaS), Technologies, and Dental Solutions. Sleep & Respiratory Care: In this division, ResMed offers a wide range of masks, devices, and accessories for the treatment of sleep apnea and other respiratory diseases. The most well-known products include the AirSense and AirMini devices, equipped with Automatic Sleep Detection and AutoSet algorithm to optimize respiratory pressure. ResMed also offers a range of CPAP masks, nasal and full face masks, as well as nasal pillow masks. Software as a Service (SaaS): ResMed's cloud-based software solutions and services are offered under the brand AirView. They include diagnostic tools, patient monitoring systems, and analysis tools. AirView allows doctors to access their patients' medical data captured by ResMed devices and monitor this data in real-time. Technologies: ResMed's Technologies division focuses on the development of advanced sensors for respiratory and sleep monitoring. Products include the S+, a smart sleep tracking system that operates without direct body contact, and the Reveal-LTE, an implant for monitoring heart and respiratory rates in patients with heart failure. Dental Solutions: ResMed has also developed products for dentistry to assist patients with mild to moderate upper airway obstruction. Products include the Narval CC, a custom-made dental device for the treatment of snoring and sleep apnea, and the Tap Pap nasal pillow oral appliance, a non-invasive mouthguard. Conclusion: ResMed is a leading provider of medical devices and solutions for the treatment of sleep apnea and other respiratory diseases. The company offers innovative products and technologies that help patients breathe better and achieve restful sleep. ResMed's cloud-based software solutions enable doctors to monitor their patients' health in real-time and develop effective diagnosis and treatment strategies. With its wide range of products, innovation, and highly qualified team of scientists, engineers, and medical professionals, ResMed will continue to play an important role in the healthcare industry. Resmed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Resmed stock

FCF Conversion Rate (FCF/EBITDA) of Resmed is 108.29 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Resmed changed from 118.63 % to 108.29 %, representing a -8.72% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Resmed since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Resmed with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Resmed

All Key Metrics — Resmed